StockTipsArenaBeta

BUY Piramal Pharma Limited — Kunal Saraogi

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byKunal SaraogiHorizon: 1 year30 Oct 2026via Zee Business (Live)

Entry₹234.1Inferred
Target₹300
Total upside +28.15%
Stop lossNot given
CMP₹238.915h ago
Active+2.05%+25.57%upside left 12 mo left
Follow Kunal Saraogi for new callsGet alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 8 other Long-term calls on PPLPHARMASee 410 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Oct, 9:22 pm IST
21 supporting6 neutral4 opposing
Supports the BUY call (21)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·30 Oct · today

6 other SEBI-registered advisors have active long-term BUY calls on this stock, with 4 issued in the last 14 days

Advisor consensus · same horizon·29 Oct · yesterday

Telecom could become one of Nifty’s biggest sectors after financials, says ICICI Securities

NewsCnbc-Tv18·28 Oct · 2d ago

(opens in new tab)

Piramal Pharma shares surge 14% as Q2 profitability improves, FY27 outlook raised

NewsCnbc-Tv18·28 Oct · 2d ago

(opens in new tab)

ICICI Securities sees telecom among Nifty's biggest sectors as tariff hike nears

NewsCnbc-Tv18·28 Oct · 2d ago

(opens in new tab)
Neutral / worth noting (6)

Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·27 Oct · 3d ago

(opens in new tab)

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 4w ago

(opens in new tab)
Weighs against the BUY call (4)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from Kunal Saraogi

Every call and its outcome